- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05461209
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)
January 27, 2023 updated by: Janssen Research & Development, LLC
A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an Anti-CD38 Antibody
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Multiple myeloma is an incurable, malignant, plasma cell disorder that accounts for approximately 18 percent (%) of hematological malignancies, making it the second most common hematologic malignancy.
Talquetamab (also known as JNJ-64407564) is a humanized immunoglobulin G4 (IgG4) bispecific antibody designed to target G Protein-coupled receptor family C group 5 member D (GPRC5D+) cells and cluster of differentiation 3 (CD3) receptor complex on T-cells.
Belantamab mafodotin is a humanized B-cell maturation antigen (BCMA)-targeting monoclonal antibody (mAb) conjugated to a cytotoxic agent maleimidocaproyl monomethyl auristatin F (MMAF) which disrupts the microtubule network, leading to cell cycle arrest and apoptosis.
This study will investigate the possible improvement of ORR or PFS with talquetamab compared with belantamab mafodotin in participants with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 mAb (alone or in combination), and whose disease is refractory to at least one proteasome inhibitor (PI) and one immunomodulatory drug (IMiD).
The study will consists of a screening phase, treatment phase (until confirmed progressive disease, start of subsequent antimyeloma therapy, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first), and post-treatment follow-up phase (until death, withdrawal of consent, loss to follow-up, or end of the study, whichever occurs first).
Safety evaluations will include a review of adverse events, physical examinations, eastern cooperative oncology group (ECOG) performance status, clinical laboratory tests, and vital signs.
Study Type
Interventional
Phase
- Phase 3
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kielce, Poland, 25-734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented multiple myeloma as defined by the criteria: a) multiple myeloma according to international myeloma working group (IMWG) diagnostic criteria b) measurable disease at screening, as assessed by central laboratory, defined by any of the following i) serum M-protein level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) ii) urine M-protein level >=200 milligram (mg)/24 hours iii) Light chain multiple myeloma without measurable M-protein in the serum or the urine: serum free light chain (sFLC) >=10 milligram per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain (FLC) ratio
- Received at least 4 prior antimyeloma therapies including an anti-cluster of differentiation 38 (CD38) monoclonal antibody (mAb) (alone or in combination) and is refractory per IMWG criteria to at least one proteasome inhibitor (PI), and one immunomodulatory drug (IMiD)
- Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at screening
- A female participant of childbearing potential must have a negative serum pregnancy test at screening, and must agree to further serum or urine pregnancy tests during the study and within 6 months after receiving the last dose of study treatment
Exclusion Criteria:
- Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients
- Stroke or seizure within 6 months prior to signing informed consent form (ICF)
- Prior or concurrent exposure to belantamab mafodotin
- Current corneal epithelial disease except mild punctate keratopathy
- Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Talquetamab
Participants will receive talquetamab subcutaneously (SC).
|
Talquetamab will be administered as subcutaneous injection.
Other Names:
|
Active Comparator: Arm B: Belantamab Mafodotin
Participants will receive belantamab intravenously (IV).
|
Belantamab Mafodotin will be administered as intravenous infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 1 year 3 months
|
ORR is defined as percentage of participants with confirmed best overall response of partial response (PR) or better according to international myeloma working group (IMWG) criteria.
|
Up to 1 year 3 months
|
Progression-free Survival (PFS)
Time Frame: Up to 1 year 3 months
|
PFS is defined as the duration from the date of randomization to either progressive disease or death, whichever comes first.
|
Up to 1 year 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Very Good Partial Response (VGPR) or Better Response Rate
Time Frame: Up to 4 years
|
VGPR or better response rate is defined as percentage of participants with best overall response of VGPR or better according to IMWG criteria.
|
Up to 4 years
|
Complete Response (CR) or Better Response Rate
Time Frame: Up to 4 years
|
CR or better response is defined as percentage of participants with best overall response of CR or better according to IMWG criteria.
|
Up to 4 years
|
Overall Survival (OS)
Time Frame: Up to 4 years
|
OS is defined as the time from randomization to date of death due to any cause.
|
Up to 4 years
|
Time to Progression on the First Subsequent Line of Therapy or Death, Whichever Comes First (PFS2)
Time Frame: Up to 4 years
|
PFS2 is defined as time from randomization to progression on the first subsequent line of therapy or death due to any cause, whichever comes first.
|
Up to 4 years
|
Number of Participants with Adverse Events (AEs)
Time Frame: Up to 4 years
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
|
Up to 4 years
|
Number of Participants with AEs by Severity
Time Frame: Up to 4 years
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death).
Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
|
Up to 4 years
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
Time Frame: Up to 4 years
|
Number of participants with abnormalities in clinical laboratory assessments (such as serum chemistry and hematology [including coagulation]) will be reported.
|
Up to 4 years
|
Serum Concentration of Talquetamab
Time Frame: Up to 4 years
|
Serum samples will be analyzed to determine concentrations of talquetamab using a validated, specific, and sensitive electrochemiluminescent immunoassay (ECLIA) method.
|
Up to 4 years
|
Number of Participants with Anti-drug Antibodies (ADAs) to Talquetamab
Time Frame: Up to 4 years
|
Number of participants with ADAs to talquetamab will be reported.
|
Up to 4 years
|
Titers of ADAs to Talquetamab
Time Frame: Up to 4 years
|
Titers of ADAs to talquetamab will be reported.
|
Up to 4 years
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
Time Frame: Baseline up to 4 years
|
The EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties).
The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales.
The item and scale scores are transformed to a 0 to 100 scale.
A high scale score represents a higher response level.
|
Baseline up to 4 years
|
Change from Baseline in EuroQol 5-Dimension Questionnaire 5-Level (EQ-5D-5L)
Time Frame: Baseline up to 4 years
|
EQ-5D-5L is a generic measure of health status.
For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses.
The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
|
Baseline up to 4 years
|
Change from Baseline in EuroQol 5-Dimension Questionnaire 5-Level (FACT-G)
Time Frame: Baseline up to 4 years
|
FACT-G is a 27-item questionnaire designed to measure 4 domains of HRQoL in cancer patients: physical, social, emotional, and functional well-being.
In its Physical Well-Being subscale, the FACT-G includes a question concerning side effect bother (item GP5: "I am bothered by side effects of treatment"), rated on a 5-point Likert scale from "not at all" to "very much."
This single item will be included as an overall summary measure of the burden of treatment toxicities compared with each other.
|
Baseline up to 4 years
|
Time to Sustained Worsening in EORTC-QLQ-C30
Time Frame: Up to 4 years
|
EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties).
The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales.
The item and scale scores are transformed to a 0 to 100 scale.
A high scale score represents a higher response level.
|
Up to 4 years
|
Time to Sustained Worsening in EQ-5D-5L
Time Frame: Up to 4 years
|
The EuroQol 5-Dimension Questionnaire 5-Level (EQ-5D-5L) is a generic measure of health status.
For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses.
The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
|
Up to 4 years
|
Time to Sustained Worsening in FACT-G
Time Frame: Up to 4 years
|
FACT-G is a 27-item questionnaire designed to measure 4 domains of HRQoL in cancer patients: physical, social, emotional, and functional well-being.
In its Physical Well-Being subscale, the FACT-G includes a question concerning side effect bother (item GP5: "I am bothered by side effects of treatment"), rated on a 5-point Likert scale from "not at all" to "very much."
This single item will be included as an overall summary measure of the burden of treatment toxicities compared with each other.
|
Up to 4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2022
Primary Completion (Actual)
November 15, 2022
Study Completion (Actual)
November 15, 2022
Study Registration Dates
First Submitted
July 13, 2022
First Submitted That Met QC Criteria
July 13, 2022
First Posted (Actual)
July 18, 2022
Study Record Updates
Last Update Posted (Estimate)
January 30, 2023
Last Update Submitted That Met QC Criteria
January 27, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- CR109235
- 2022-001442-38 (EudraCT Number)
- 64407564MMY3008 (Other Identifier: Janssen Research and Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/ Refractory Multiple Myeloma
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
Carl Ola Landgren, MD, PhDBristol-Myers SquibbRecruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Regeneron PharmaceuticalsActive, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...CompletedMultiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Ionis Pharmaceuticals, Inc.Active, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
TakedaCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States, Canada
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
Clinical Trials on Talquetamab
-
Memorial Sloan Kettering Cancer CenterJanssen PharmaceuticalsRecruitingMultiple MyelomaUnited States
-
Janssen Research & Development, LLCRecruitingHematological MalignanciesUnited States, Netherlands, Spain, Belgium
-
Janssen Research & Development, LLCNo longer availableRelapsed or Refractory Multiple MyelomaBelgium, Iceland, Portugal, Slovenia
-
Janssen Research & Development, LLCApproved for marketingRelapsed or Refractory Multiple MyelomaBrazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
-
Janssen Research & Development, LLCRecruitingHematological MalignanciesUnited States, Belgium, Korea, Republic of, China, Germany, Israel, Spain, Netherlands, Japan, France, Poland
-
Janssen Pharmaceutical K.K.Active, not recruiting
-
Janssen Research & Development, LLCRecruitingMultiple MyelomaUnited States, Korea, Republic of, Canada, Israel, Spain, Japan, Australia
-
Carl Ola Landgren, MD, PhDJanssen Scientific Affairs, LLCRecruitingMultiple MyelomaUnited States
-
CelgeneRecruitingMultiple MyelomaUnited States, France, Germany, Spain, United Kingdom, Italy
-
Janssen Research & Development, LLCRecruitingRelapsed/ Refractory Multiple MyelomaUnited States, Germany, Spain, France